COST-EFFECTIVENESS OF BRENTUXIMAB VEDOTIN IN RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN TAIWAN

被引：1
|
作者：
Zou, D. [1 ]
Kendall, R. [1 ]
Lin, Q. [2 ]
Huang, Y. [2 ]
Tieng, J. [3 ]
Tseng, J. [3 ]
Sajosi, P. [4 ]
机构：
[1] ICON Plc, Vancouver, BC, Canada
[2] Kantar Hlth, Taipei, Taiwan
[3] Takeda Pharmaceut Taiwan, Taipei, Taiwan
[4] Takeda Pharmaceut Int AG, Zurich, Switzerland
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.08.705
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CE2
引用
收藏
页码：A811 / A811
页数：1
相关论文
共 50 条
  • [21] Brentuximab vedotin for previously untreated systemic anaplastic large cell lymphoma
    Calleja, Anne
    Bouclet, Florian
    BULLETIN DU CANCER, 2021, 108 (01) : 12 - 13
  • [22] Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China
    Xie, Shitong
    Sheng, Yanan
    Chuang, Ling-Hsiang
    Wu, Jing
    HEALTH ECONOMICS REVIEW, 2024, 14 (01):
  • [23] Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study
    Fukuhara, Noriko
    Yamamoto, Go
    Tsujimura, Hideki
    Chou, Takaaki
    Shibayama, Hirohiko
    Yanai, Tomoko
    Shibuya, Kazunori
    Izutsu, Koji
    LEUKEMIA & LYMPHOMA, 2020, 61 (01) : 176 - 180
  • [24] Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update
    Advani, Ranjana H.
    Shustov, Andrei R.
    Brice, Pauline
    Bartlett, Nancy L.
    Rosenblatt, Joseph D.
    Illidge, Tim
    Matous, Jeffrey
    Ramchandren, Radhakrishnan
    Fanale, Michelle A.
    Connors, Joseph M.
    Yang, Yin
    Kennedy, Dana A.
    Pro, Barbara
    BLOOD, 2011, 118 (21) : 204 - 204
  • [25] Resolution of malignant cutaneous lesions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma
    Advani, Ranjana
    Pro, Barbara
    Kennedy, Dana
    Fanale, Michelle
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB4 - AB4
  • [26] Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland
    Parker, Christopher
    Woods, Beth
    Eaton, James
    Ma, Esprit
    Selby, Ross
    Benson, Eugene
    Engstrom, Andreas
    Sajosi, Peter
    Briggs, Andrew
    Bonthapally, Vijayveer
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (01) : 8 - 18
  • [27] COST-EFFECTIVENESS EVALUATION OF BRENTUXIMAB VEDOTIN FOR REFRACTORY/RELAPSED HODGKIN LYMPHOMA: A COMPARATIVE ANALYSIS OF THE RESULTS OF MEXICO AND VENEZUELA
    Meza-Torres, B.
    Gay, J. G.
    Jakouloff, D. E.
    VALUE IN HEALTH, 2014, 17 (07) : A637 - A637
  • [28] Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
    Forero-Torres, Andres
    Berryman, R. Brian
    Advani, Ranjana H.
    Bartlett, Nancy L.
    Chen, Robert W.
    Fanale, Michelle A.
    Gopal, Ajay K.
    O'Connor, Owen A.
    Olshefski, Randal
    Smith, Scott E.
    Grove, Laurie E.
    Matous, Jeffrey
    BLOOD, 2011, 118 (21) : 1585 - 1586
  • [29] THE COST-EFFECTIVENESS OF BRENTUXIMAB VEDOTIN IN HODGKIN LYMPHOMA IN SWEDEN
    Engstrom, A.
    VALUE IN HEALTH, 2014, 17 (07) : A639 - A639
  • [30] Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
    Pro, Barbara
    Advani, Ranjana
    Brice, Pauline
    Bartlett, Nancy L.
    Rosenblatt, Joseph D.
    Illidge, Tim
    Matous, Jeffrey
    Ramchandren, Radhakrishnan
    Fanale, Michelle
    Connors, Joseph M.
    Yang, Yin
    Sievers, Eric L.
    Kennedy, Dana A.
    Shustov, Andrei
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (18) : 2190 - 2196
12345